Evidence map›Paper›PMID 24489709›Full record

ArticlePloS one2014

ENDOGLIN is dispensable for vasculogenesis, but required for vascular endothelial growth factor-induced angiogenesis.

Zhen Liu, Franck Lebrin, Janita A Maring, Sander van den Driesche, Stieneke van der Brink, Maarten van Dinther, Midory Thorikay, Sabrina Martin, Kazuki Kobayashi, Lukas J A C Hawinkels and 9 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
6.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 80 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Glyceraldehyde 3-Phosphate Dehydrogenase and Galectin fromAnimals : an open access journal from MDPI · 2025
    Article
  5. DMP1-mediated transformation of DPSCs to CD31Frontiers in cell and developmental biology · 2025
    Article
  6. Defining the clinical validity of genes reported to cause pulmonary arterial hypertension.Genetics in medicine : official journal of the American College of Medical Genetics · 2023
    Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Endoglin Targeting: Lessons Learned and Questions That Remain.International journal of molecular sciences · 2020
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 7 institutions in 5 countries.

Zhen LiuDepartment of Molecular Cell Biology, Cancer Genomics Centre, Centre for Biomedical Genetics, Leiden University Medical Center, Leiden, The Netherlands.
Franck LebrinHubrecht Institute, Utrecht, The Netherlands ; Center for Interdisciplinary Research in Biology (CIRB), CNRS UMR 7241/INSERM U1050, Collège de France, Paris, France.
Janita A MaringDepartment of Molecular Cell Biology, Cancer Genomics Centre, Centre for Biomedical Genetics, Leiden University Medical Center, Leiden, The Netherlands.
Sander van den DriescheHubrecht Institute, Utrecht, The Netherlands.
Stieneke van der BrinkHubrecht Institute, Utrecht, The Netherlands.
Maarten van DintherDepartment of Molecular Cell Biology, Cancer Genomics Centre, Centre for Biomedical Genetics, Leiden University Medical Center, Leiden, The Netherlands.
Midory ThorikayDepartment of Molecular Cell Biology, Cancer Genomics Centre, Centre for Biomedical Genetics, Leiden University Medical Center, Leiden, The Netherlands.
Sabrina MartinCenter for Interdisciplinary Research in Biology (CIRB), CNRS UMR 7241/INSERM U1050, Collège de France, Paris, France.
Kazuki KobayashiDepartment of Molecular Cell Biology, Cancer Genomics Centre, Centre for Biomedical Genetics, Leiden University Medical Center, Leiden, The Netherlands.
Lukas J A C HawinkelsDepartment of Molecular Cell Biology, Cancer Genomics Centre, Centre for Biomedical Genetics, Leiden University Medical Center, Leiden, The Netherlands.
Laurens A van MeeterenDepartment of Molecular Cell Biology, Cancer Genomics Centre, Centre for Biomedical Genetics, Leiden University Medical Center, Leiden, The Netherlands.
Evangelia PardaliDepartment of Molecular Cell Biology, Cancer Genomics Centre, Centre for Biomedical Genetics, Leiden University Medical Center, Leiden, The Netherlands.
Jeroen KorvingHubrecht Institute, Utrecht, The Netherlands.
Michelle LetarteMolecular Structure and Function Program, The Hospital of Sick Children, Department of Immunology and Heart and Stroke Richard Lewar Center of Excellence, University of Toronto, Toronto, Ontario, Canada.
Helen M ArthurInstitute of Genetic Medicine, Newcastle University, International Centre for Life, Newcastle upon Tyne, United Kingdom.
Charles TheuerTracon Pharmaceuticals, San Diego, California, United States of America.
Marie-José GoumansDepartment of Molecular Cell Biology, Cancer Genomics Centre, Centre for Biomedical Genetics, Leiden University Medical Center, Leiden, The Netherlands.
Christine MummeryHubrecht Institute, Utrecht, The Netherlands ; Department of Anatomy and Embryology, Leiden University Medical Center, Leiden, The Netherlands.
Peter ten DijkeDepartment of Molecular Cell Biology, Cancer Genomics Centre, Centre for Biomedical Genetics, Leiden University Medical Center, Leiden, The Netherlands.
Cancer Genomics Centre · NLLeiden University Medical Center · NLHubrecht Institute for Developmental Biology and Stem Cell Research · NLCentre National de la Recherche Scientifique · FRNewcastle University · GBTracon Pharmaceuticals (United States) · USUniversity of Toronto · CA

Funding

British Heart Foundation RG/12/2/29416
6 · The paper itself

Abstract

ENDOGLIN (ENG) is a co-receptor for transforming growth factor-β (TGF-β) family members that is highly expressed in endothelial cells and has a critical function in the development of the vascular system. Mutations in Eng are associated with the vascular disease known as hereditary hemorrhagic telangiectasia type l. Using mouse embryonic stem cells we observed that angiogenic factors, including vascular endothelial growth factor (VEGF), induce vasculogenesis in embryoid bodies even when Eng deficient cells or cells depleted of Eng using shRNA are used. However, ENG is required for the stem cell-derived endothelial cells to organize effectively into tubular structures. Consistent with this finding, fetal metatarsals isolated from E17.5 Eng heterozygous mouse embryos showed reduced VEGF-induced vascular network formation. Moreover, shRNA-mediated depletion and pharmacological inhibition of ENG in human umbilical vein cells mitigated VEGF-induced angiogenesis. In summary, we demonstrate that ENG is required for efficient VEGF-induced angiogenesis.

Indexed as

AnimalsCell DifferentiationEndoglinFlow CytometryFluorescent Antibody TechniqueHumansHuman Umbilical Vein Endothelial CellsIntracellular Signaling Peptides and ProteinsMiceNeovascularization, PhysiologicVascular Endothelial Growth Factor AEndoglinEng protein, mouseIntracellular Signaling Peptides and ProteinsVascular Endothelial Growth Factor A

Identifiers

PMID24489709
PMCPMC3904881
OpenAlexW2079213548

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.